"Bear is it so important to evaluate BOM on event rates when the top-line is based on time to the first occurrence. In other words, if the ABL wins on the least number of 3 point mace events and not statistically significant as compared to placebo when it comes to time to the first occurrence of each event, why do we pay so much attention comparing the number of placebo & apabetalone event rates?"

Lots of unknowns. Lots of possibilities. Every bit of good information would be helpful in narrowing things down.

BDAZ